Biotech Showcase™ 2016: Corbus sees 2016 as pivotal year

February 2, 2016
With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Dr. Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabionoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: Canaan Partners outlines funding priorities
Biotech Showcase™ 2016: Interview: Canaan Partners outlines funding priorities

After raising its 10th fund in 2014, Canaan Partners has been actively investing in early stage US biopharm...

Next Video
Biotech Showcase™ 2016: Grünenthal reveals plans to maintain robust growth following strong 2015
Biotech Showcase™ 2016: Grünenthal reveals plans to maintain robust growth following strong 2015

While other pharma majors have struggled against a number of headwinds, Grünenthal GmbH saw a solid year of...